Coya Therapeutics and Dr Reddy's link up on ALS research

6 December 2023

Texas, USA-based Coya Therapeutics (Nasdaq: COYA) saw its shares rise 2.5% to $7.46, on news of deal with India’s Dr Reddy’s Laboratories (BSE: 500124) on the development and license agreement for the development and commercialization of COYA-302, an investigational combination therapy for the treatment of amyotrophic lateral sclerosis (ALS).

Coya has granted Dr Reddy’s an exclusive license to commercialize COYA-302, a proprietary co-pack kit containing combination of low dose interleukin (IL)-2 and CTLA-4 Ig (abatacept) in the USA, Canada, the European Union and the UK for ALS. This agreement is in addition to the in-licensing agreement with Dr Reddy’s signed in early 2023.

Coya retains the right to commercialize COYA-302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA-302 for patients with ALS in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK